COMPANY

AgonOx, Inc.

HQ: Portland, OR source · agonox.com ↗ · West Coast

Also known as AgonOx · 4 sources

Keywords: oncology solid tumors HNSCC Melanoma Gynecologic Cancer Colorectal Cancer Lung Cancer Urogenital Cancer breast cancer

Location: Portland, OR · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $978K (SBIR Phase II 1R44CA314796-01, new, notice Sep 17, 2026). NIH RePORTER 1R44CA314796-01 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 1R44CA314796-01
  Organization: AGONOX, INC.; City/State: PORTLAND, OR; Project number: 1R44CA314796-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 977639; Administering IC: National Cancer Institute; Project title: Enriching and expanding tumor-reactive CD8 T-cells to treat breast cancer; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Jun 19, 2023 Trial start Phase 1: Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors source ↗

Dec 31, 2026 (ESTIMATED) · Phase 1 · Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors · NCT05902520

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT05902520	Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors	Phase 1	Active, not recruiting	Jun 19, 2023	Dec 31, 2026 (estimated)

Annual award amounts. Total $1.3M.

Sep 17, 2026 NIH award 1R44CA314796-01 FY2026: $977,639 awarded for that fiscal year; activity R44 (SBIR); PI WEINBERG, ANDREW D.; recipient as written: AGONOX, INC., PORTLAND, OR. Enriching and expanding tumor-reactive CD8 T-ce source ↗
May 12, 2014 NIH award 5R43CA159797-02 FY2014: $106,505 awarded for that fiscal year; activity R43 (SBIR); PI TRIGLIA, DENNIS; recipient as written: AGONOX, INC., PORTLAND, OR. Humanization of a mouse anti-OX40 monoclonal antibod source ↗
Jun 8, 2012 NIH award 1R43CA159797-01A1 FY2012: $187,201 awarded for that fiscal year; activity R43 (SBIR); PI TRIGLIA, DENNIS; recipient as written: AGONOX, INC., PORTLAND, OR. Humanization of a mouse anti-OX40 monoclonal antib source ↗